HCV Vaccine Heterodimeric E1E2 Polypeptides Broad Genotype Protection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for compositions and methods that effectively induce immune responses to Hepatitis C virus (HCV), as current vaccines and treatments are inadequate in providing broad-spectrum protection against various HCV genotypes.
Innovation Solution
The development of heterodimeric polypeptides comprising variant HCV E2 and E1 proteins, or their variants, which include T-cell epitopes from other HCV proteins or non-HCV proteins like cholera toxin or tetanus toxin, to enhance immune response induction.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If recombinant envelope glycoproteins (rE1E2) from a single genotype are used as vaccine antigens, then protection against homologous and heterologous genotype 1a viral challenge is achieved, but broad-spectrum protection against multiple HCV genotypes is insufficient
Solution Approach 1:
The patent combines multiple HCV envelope glycoprotein variants (E1 and E2 from different genotypes) into a single vaccine composition. This merging of antigens from multiple genotypes enables the vaccine to elicit T-cell responses against conserved epitopes across different HCV strains, thereby achieving broad-spectrum protection while maintaining reliable immunogenicity.
Solution Approach 2:
The vaccine composition is designed to serve multiple functions by including E1 and E2 glycoprotein variants from different HCV genotypes. This multi-functional antigen design allows a single vaccine to target multiple genotypes simultaneously, enhancing adaptability and versatility without requiring separate vaccines for each genotype.
2Adaptability or versatility
If T-cell epitopes from multiple HCV proteins are incorporated into the vaccine composition, then broad T-cell responses against multiple genotypes are induced, but the complexity of the vaccine composition increases
Solution Approach 1:
The vaccine composition is segmented into distinct functional components: E1 glycoprotein variants, E2 glycoprotein variants, and adjuvants. Each segment contributes specific T-cell epitopes from different HCV proteins, allowing the complex immunogenic response to be achieved through organized, modular antigen presentation rather than a chaotic mixture.
Solution Approach 2:
The vaccine employs a composite antigen structure where E1 and E2 glycoprotein variants are combined in specific ratios with selected adjuvants. This composite formulation optimizes the presentation of multiple T-cell epitopes while managing composition complexity through defined structural organization and standardized manufacturing parameters.
3Ease of manufacture
If envelope glycoproteins are expressed as individual subunits, then production is simplified, but proper folding and stability are compromised
Solution Approach 1:
The patent uses expression systems with chaperone proteins or fusion tags as intermediaries to assist in the proper folding of individual E1 and E2 glycoprotein subunits during production. These intermediaries facilitate correct disulfide bond formation and tertiary structure establishment, ensuring stability while maintaining the benefit of simplified individual subunit expression and purification.
Data Source
Figure 1A
Figure 1B
Figure 1C
AI summary
The present disclosure provides heterodimeric polypeptides comprising: 1) a variant hepatitis C virus (HCV) E2 polypeptide and an HCV El polypeptide; 2) a variant HCV El polypeptide and an HCV E2 polypeptide; or 3) a variant HCV El polypeptide and a variant HCV E2 polypeptide, where the variant HCV E2 polypeptide and/or the HCV El polypeptide comprises one or more T cell epitopes, present in an HCV polypeptide other than an HCV El polypeptide or an HCV E2 polypeptide. The present disclosure provides nucleic acids encoding a polyprotein that includes El and variant E2, E2 and variant El, or variant E2 and variant El. The present disclosure provides a method of producing an E1/E2 heterodimer of the present disclosure. The present disclosure provides a method of inducing an immune response in an individual. The present disclosure provides variant E2 polypeptides and variant E1 polypeptides; and nucleic acids encoding same.